The RELATIVITY-098 trial showed no RFS improvement with nivolumab plus relatlimab versus nivolumab alone in resected stage III-IV melanoma. The trial was terminated as it failed to meet its primary ...

BGB-B2033, a bispecific antibody, targets 4-1BB and GPC3, showing potential in advanced hepatocellular carcinoma (HCC) ...

Findings from a study on the utility of ultrasensitive circulating tumor DNA (ctDNA) as a predictive biomarker for patients ...

Laura Huppert, MD, highlights patient-reported outcomes from the phase 3 ASCENT-04 trial which compared first-line treatment ...

Laura Huppert, MD, discusses the results of the phase 3 ASCENT-03 trial, which compared the antibody-drug conjugate ...

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to include duvelisib (Copiktra) as a category 2A treatment option for cutaneous T-cell ...

In December 2025, the FDA accepted for priority review the supplemental biologics license application for nivolumab-AVD for the treatment of adult and pediatric patients 12 years and older with ...

The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...

This preview introduces the central themes of the upcoming Evolving Paradigms in Oncology program focused on targeted therapies and CELMoD agents in multiple myeloma. Dr. Nisha Joseph offers an early ...

PERSEUS trial findings suggest that modern myeloma therapies could lead to survival rates similar to age-matched controls. KLN-1010, an off-the-shelf gene therapy, demonstrated promising MRD-negative ...

RAD 101 demonstrated significant tumor uptake and 92% concordance with MRI in a phase 2b trial, enhancing confidence in its diagnostic potential. The agent targets fatty acid synthase, aiding in ...